Prolintane
Viewing r1 — May 13, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Prolintane is a synthetic stimulant of the pyrrolidine class. It is structurally related to pyrovalerone, distinguished by the absence of a beta-keto group. Prolintane is a dopamine and norepinephrine reuptake inhibitor with serotonin-releasing activity at human transporters,[1] producing its effects by increasing catecholamine availability in reward and attention circuits.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized in the 1950s by Thomae (later Boehringer Ingelheim), prolintane was marketed across Europe as Katovit and Villescon for fatigue, narcolepsy, and ADHD. Abuse liability concerns led to its withdrawal from pharmaceutical markets by 2001, after which it resurfaced on research chemical markets.[1][2] It remains unscheduled in most major jurisdictions but is prohibited in athletic competition.[3]
Subjective effects include wakefulness, cognitive enhancement, mood elevation, and increased focus. The experience at common doses is functional rather than euphoric — a clean, focused stimulation closer to methylphenidate than cocaine, without pronounced peripheral intensity.[4] Insomnia, nervousness, irritability, and compulsive redosing urges are characteristic unsought effects.[5]
Prolintane demonstrates moderate abuse potential in rodent models, with no published human dependence or withdrawal data.[4] Cardiovascular risk escalates sharply at supratherapeutic doses — rodent studies document hERG channel inhibition and QT prolongation, markers of potentially fatal heart rhythm disturbances.[6] The evidence base is thin: no controlled human toxicity studies exist, and a species-dependent serotonergic mechanism discovered in 2025 means prior safety assessments underestimate interaction risks.[1]
History[edit]
Discovery
Prolintane was synthesized in the 1950s by Thomae, a German pharmaceutical company later absorbed into Boehringer Ingelheim, as part of a program developing amphetamine analogs with milder side-effect profiles.[7] Patents were filed in Germany (1956) and the United Kingdom (1959), positioning the compound as a moderate-potency psychostimulant for clinical use.
Clinical use
Boehringer Ingelheim marketed prolintane across Europe as Villescon from the early 1960s for fatigue and asthenia.[8] In Spain, the firm FHER sold it as Katovit — orange-coated tablets combining prolintane with vitamins, available over the counter at low cost.[9] Clinical indications expanded to include ADHD, narcolepsy, orthostatic hypotension, and depressive syndromes across South Africa, Australia, and multiple European nations.[5]
Withdrawal and modern use
Katovit was withdrawn from the Spanish market in 2001 due to abuse concerns,[8][7] and broader medical use was discontinued as abuse liability became increasingly recognized.[1] Cheap over-the-counter availability had already facilitated recreational use — Katovit tablets circulated at rave parties in southwest France,[9] and the compound was characterized as a "masked amphetamine" in Spanish abuse patterns.[10] Since the mid-2010s, prolintane has appeared on research chemical markets as a novel psychoactive substance.[2]
Prolintane's reputation in drug culture centers on the Katovit brand — inexpensive, vitamin-fortified tablets that circulated as a cheap stimulant alternative at rave parties in southern Europe before withdrawal.[9] Martinez-Mir et al. termed it a "masked amphetamine," reflecting its ability to pass as a benign vitamin supplement.[10] The compound is also prohibited under WADA's S6 Stimulants category[3] and banned by the NCAA.[11]
Chemistry[edit]
Structural class
Prolintane belongs to the pyrrolidine class of stimulants, sharing a substituted pyrrolidine scaffold with pyrovalerone and the synthetic cathinone series. The parent structure consists of a phenyl ring connected via a methylene bridge to a pentyl chain bearing a pyrrolidine nitrogen at the 2-position. Prolintane is the des-keto parent of pyrovalerone — the absence of a carbonyl group at the benzylic position distinguishes it from its beta-keto structural analog,[12] placing it at the boundary between classical amphetamine analogs and newer pyrovalerone-type cathinones.
Molecular structure
| Molecular formula | C₁₅H₂₃N |
| Molecular weight | 217.35 g/mol |
The molecule features a five-membered pyrrolidine ring (saturated nitrogen heterocycle) attached to the 2-position of a 1-phenylpentane chain. The phenyl ring is unsubstituted, and the alkyl chain extends three carbons beyond the nitrogen-bearing center.
No published characterization of prolintane's melting point, solubility profile, or stability under standard storage conditions was identified. The free base is expected to be a liquid or low-melting solid based on molecular weight and structural analogy to other phenylalkylamine free bases. Katovit tablets contained prolintane as the hydrochloride salt.[9]
Stereochemistry
Prolintane possesses one chirality center at the carbon bearing the pyrrolidine nitrogen. The compound is marketed and studied as a racemate — no published data establish differential pharmacological activity between the (R)- and (S)-enantiomers.[13]
Pharmacology[edit]
Mechanism of action
Prolintane functions primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI), blocking the DAT (DAT) and NET (NET) to elevate synaptic dopamine and norepinephrine. This mechanism is pharmacologically analogous to cocaine and methylphenidate — prolintane inhibits transporter-mediated reuptake without inducing vesicular monoamine release.[1][14]
The distinction was established through neurochemical studies showing that prolintane increases intraneuronal dopamine metabolite (DOPAC) concentrations — a pattern characteristic of reuptake inhibitors, not releasers like amphetamine.[14]
A 2025 study revealed a critical addition: prolintane also acts as a SERT substrate at human serotonin transporters, inducing serotonin efflux — making it a hybrid compound.[1] Serotonergic potency was at least tenfold weaker than dopaminergic potency. This activity was not observed in rat tissue, meaning decades of rat-based pharmacology underestimated prolintane's serotonergic effects in humans.[1]
An earlier case report described prolintane as a dopamine releaser,[15] but the weight of evidence from multiple studies firmly supports reuptake inhibition as the primary catecholaminergic mechanism.[1][14]
Pharmacokinetics
No published human pharmacokinetic studies exist for prolintane. Oral bioavailability, peak plasma time, half-life, volume of distribution, and protein binding are all undocumented.
Metabolism proceeds through sequential oxidation of the pyrrolidine ring: formation of an iminium ion intermediate, then a carbinolamine, and finally a lactam product.[16] Species differences in lactam formation rates arise from variation in aldehyde oxidase and CYP450 enzyme expression.[16] The specific CYP enzymes responsible for prolintane metabolism in humans have not been identified.
Duration data from community reporting — onset 20–60 minutes, peak 2–3 hours, total 4–6 hours for oral administration[17] — are consistent with controlled study observations: cognitive enhancement at 2.5 hours post-dose[18] and REM suppression concentrated in the first 2 hours of post-dose sleep.[19] Formal pharmacokinetic confirmation is lacking.
Neuroscience[edit]
Where it acts
Prolintane potentiates catecholamine signaling in two principal circuits. In the mesolimbic mesolimbic pathway, it elevates striatal dopamine — the neural substrate of stimulant reward — producing conditioned place preference and self-administration in rodents, though with less dopamine release than methamphetamine.[4]
In prefrontal cortex, dopamine and norepinephrine enhancement supports the cognitive sharpening observed in human studies — improved sustained attention at 2.5 hours post-dose[18] — likely through modulation of working memory and executive function circuits.
Why it matters
Prolintane's profile maps onto the incentive salience model of addiction: DAT blockade potentiates the wanting signal (motivational drive to seek the drug), while subjective liking appears moderate — only 38.57% cocaine-appropriate responding in discrimination tests.[4] This dissociation may explain compulsive redosing without extreme euphoria.
Locomotor sensitization in rodents[4] suggests progressive enhancement of dopamine responses with repeated exposure, a neuroadaptation linked to escalating use patterns. Separately, rodent studies show microglial activation following prolintane — a neuroinflammatory marker that may disrupt synaptic contacts.[6]
The most significant open question concerns the serotonin-releasing activity identified only at human transporters[1]: whether this component affects subjective experience, cardiovascular risk, or interaction profiles is entirely unstudied. No data exist on prolintane's effects on neuroplasticity markers, and the rodent microglial activation findings[6] leave open whether chronic exposure produces neurotoxicity in humans. The enantiomers have never been resolved — whether one isomer carries the majority of pharmacological activity is unknown.
Subjective Effects[edit]
Prolintane's character is shaped by its dual catecholaminergic mechanism — DAT and NET reuptake inhibitor producing clean, focused stimulation without the peripheral intensity of amphetamine. The experience is strongly dose-dependent: therapeutic doses produce subtle cognitive sharpening and wakefulness with minimal subjective awareness of intoxication, while supratherapeutic doses shift toward pronounced stimulation, compulsive redosing urges, and anxiety. Set, setting, and individual catecholamine tone modulate the experience significantly.
Among NDRI stimulants, prolintane sits between methylphenidate and cocaine in reinforcing efficacy — producing reward in rodent models but only partial substitution for cocaine in discrimination paradigms.[4] At common oral doses the subjective experience aligns more closely with methylphenidate: functional rather than euphoric, with a notably mild cardiovascular profile at therapeutic doses.[18]
Effect Grid
Common doses produce clear stimulation with noticeable focus enhancement, thought acceleration, and wakefulness. Cognitive throughput improves measurably — controlled studies confirm significant performance gains on cognitive tasks at the lower end of this range. Mood elevation becomes apparent, though cognitive euphoria remains moderate rather than intense. The compulsive redosing urge may emerge at this level.
Physically, appetite suppression becomes pronounced. Stimulation is clear but typically smooth rather than jittery. Dose-dependent REM suppression intensifies — at 15-30 mg, both delayed REM onset and reduced total REM sleep are documented, with increased awakenings during early-night sleep.
Functional impairment is minimal during the active period, but insomnia is likely if taken within 6 hours of intended sleep. The 4-6 hour total duration is manageable for daytime use.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Pupil dilation · Muscle tension · Restlessness · Dry mouth · Insomnia · Dehydration sensation · Heart rate perception changes · Physical fatigue · Excessive sweating · Headache · Sexual arousal enhancement · Bruxism · Abnormal heartbeat · Involuntary body movements · Dizziness · Nausea · Trembling · Diarrhea
Dry mouth · Insomnia · Dehydration sensation · Heart rate perception changes · Physical fatigue · Excessive sweating · Headache · Sexual arousal enhancement · Bruxism · Involuntary body movements · Dizziness · Nausea · Trembling · Diarrhea
Motivation enhancement · Cognitive fatigue · Thought organization · Information processing enhancement · Analysis enhancement · Motivation suppression · Creativity enhancement · Thought deceleration · Thought disorganization
Analysis enhancement · Motivation suppression · Creativity enhancement · Thought deceleration · Thought disorganization
Anhedonia · Dysphoria
Flow state · Sociability enhancement
Timeline
Gradual awareness of mild stimulation and emerging wakefulness. Subtle shift in baseline alertness without clear cognitive effects.
Stimulation builds steadily. Focus sharpens, mood elevates, and cognitive throughput begins to improve. Physical restlessness may begin.
Maximum stimulation with clear focus enhancement, thought acceleration, appetite suppression, and sustained wakefulness. Cognitive performance measurably improved at therapeutic doses.
Stimulation gradually declines. Residual wakefulness persists while focus and mood elevation recede. Irritability or restlessness may surface.
Residual cognitive fatigue, potential dysphoria, and lingering appetite changes. Insomnia may persist if taken late in the day.
⚠ Avoid driving during this period — residual cognitive fatigue and impaired reaction time may persist for several hours after subjective stimulation has resolved.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · methylphenidate · pyrovalerone
Toxicity
Acute toxicity
No lethal dose has been published for prolintane in any species, and no controlled human toxicity data exist.safety citation needed Overdoses may produce hallucinations, psychosis, and death.[5] Both documented clinical cases involved multiple substances — preventing isolation of prolintane's individual toxicological contribution.[5]
Cardiovascular effects
Rodent studies document hERG potassium channel inhibition — a standard marker for drug-induced QT prolongation and dangerous heart rhythm disturbances.[6] The study authors concluded that risk of ventricular arrhythmia "cannot be excluded".[6]
At therapeutic oral doses (10–20 mg), prolintane produced minimal cardiovascular changes in a controlled human comparison.[18] This suggests a dose-dependent risk profile, with supratherapeutic doses posing disproportionately greater cardiac danger.
Neurotoxicity
Rodent studies show microglial activation — a marker of brain inflammation — following prolintane administration, with reduced motor coordination in both mice and rats.[6] No human neurotoxicity data exist.
Chronic toxicity
No published studies assess organ damage, cognitive decline, or cardiovascular remodeling with repeated prolintane exposure in humans or animals.safety citation needed
Pregnancy
Prolintane was detected in a case involving fetal death in the womb,[5] though concurrent use of multiple other substances prevents causal attribution. No reproductive safety or developmental toxicity data exist. The compound should not be assumed safe in pregnancy.safety citation needed
Psychological risks
Visual hallucinations have been documented in overdose settings[5] and during chronic therapeutic-dose combination with diphenhydramine.[15] In the latter case, hallucinations developed over two months and were attributed to pharmacological kindling — progressive sensitization of dopamine pathways producing hallucinatory experiences at previously tolerated doses.[15]
Insomnia, nervousness, and irritability are documented side effects at therapeutic doses.[5] Dose-dependent REM sleep suppression is confirmed,[20] and extended wakefulness at higher doses may precipitate sleep-deprivation-related psychological disturbance. DAT-inhibiting stimulants as a class carry risk of precipitating psychosis in predisposed individuals.
Tolerance and dependence
No published human tolerance or dependence studies exist. Rodent behavioral pharmacology confirms moderate abuse potential: prolintane produces conditioned place preference, self-administration, striatal dopamine elevation, and locomotor sensitization, though at lower magnitudes than methamphetamine.[4]
In drug discrimination tests, prolintane only partially substituted for cocaine (38.57% cocaine-appropriate responding), positioning it at a moderate level of reinforcing efficacy.[4] The historical withdrawal of prolintane from pharmaceutical markets was explicitly motivated by abuse liability concerns.[1]
No cross-tolerance or withdrawal studies have been published. By analogy with cocaine and methylphenidate, post-use fatigue, low mood, and reduced motivation are expected, but substance-specific withdrawal data are absent.
Drug interactions
Tramadol
Tramadol inhibits serotonin and norepinephrine reuptake alongside weak opioid activity. Combined with prolintane's NET inhibition and human SERT substrate activity,[1] the combination produces compounded serotonergic excess with risk of serotonin syndrome. Tramadol also lowers seizure threshold, which stimulant co-administration may potentiate. Deaths from tramadol combined with serotonergic agents have been documented.[21][22]
MDMA
MDMA releases serotonin, dopamine, and norepinephrine and can cause serotonin syndrome and dangerous overheating at high doses.[23] Combined with prolintane, the mixture amplifies cardiovascular strain and serotonergic activity. Both substances raise body temperature; overheating risk is compounded in hot environments.
Diphenhydramine
Therapeutic-dose combination of prolintane and diphenhydramine produced visual hallucinations in one documented case after two months of concurrent use.[15]
QT-prolonging agents
Given prolintane's documented hERG channel inhibition,[6] combination with other QT-prolonging drugs (certain antibiotics, antipsychotics, methadone) carries additive risk of dangerous heart rhythm disturbances.safety citation needed
Contraindications
Heart rhythm disorders (absolute): Prolintane inhibits the hERG potassium channel and prolongs the QT interval in rodent models.[6] Pre-existing long QT syndrome is an absolute contraindication.
Concurrent QT-prolonging medication (absolute): Additive hERG inhibition makes concurrent use with other QT-prolonging agents contraindicated.safety citation needed
Pregnancy (absolute): Prolintane was detected in a case of fetal death.[5] No reproductive safety data exist.
Psychotic disorders (relative): Hallucinations and psychosis are documented overdose outcomes,[5] and hallucinations occurred at therapeutic doses in combination with diphenhydramine.[15]
Concurrent serotonergic medication (relative to absolute): The SERT substrate activity at human transporters[1] creates serotonin syndrome risk with SSRIs, SNRIs, MAOIs, tramadol, or other serotonergic agents.
Seizure disorders (relative): Stimulants as a class may lower seizure threshold.inferred
Cardiovascular disease (relative): Therapeutic doses produced minimal cardiovascular effects,[18] but hERG inhibition data warrant caution with pre-existing heart conditions.
Harm Reduction[edit]
Forms & Identification
Prolintane circulates primarily as a white to off-white powder on research chemical markets, with historical pharmaceutical forms (Katovit tablets) no longer manufactured. Because prolintane is rare in unregulated supply, the primary identification concern is confirming that the substance is actually prolintane and not a more potent stimulant or cathinone. Laboratory analysis through drug checking services provides the most reliable identification for this compound.
Guidelines
- Start at the lowest reported active dose and wait at least 90 minutes before considering redosing — onset can be gradual.
- Weigh doses with a milligram-scale balance. Volumetric dosing in solution is an alternative for small quantities.
- Avoid redosing. Prolintane's moderate wanting signal can drive compulsive redosing without matching euphoria, leading to cumulative cardiovascular strain and insomnia.
- Do not use within 6 hours of intended sleep.
- Stay hydrated but do not overhydrate — stimulants can mask thirst and fatigue cues.
- Have food available for the post-experience period; appetite suppression during use is common with stimulants.
Set & Setting
Prolintane's functional stimulant profile makes it less context-sensitive than psychedelics, but set and setting still modulate the experience. Anxiety-prone individuals or those in high-stress environments may find stimulant effects amplified into restlessness and irritability. Evening use risks disrupting sleep architecture due to confirmed REM suppression.[20]
Aftercare & integration. The comedown from prolintane may include fatigue, low mood, and irritability as dopamine and norepinephrine levels normalize. Prioritize sleep — confirmed REM suppression means sleep quality may be impaired even after stimulant effects have worn off.
Eat a nutritious meal, hydrate, and avoid caffeine or other stimulants for 24 hours. If compulsive redosing occurred during use, reflect on the pattern before the next opportunity — prolintane's moderate wanting signal can establish habits without the user recognizing the progression.
Recovery & Support
Prolintane's moderate reinforcing efficacy means habitual use patterns can develop gradually. If use has become compulsive or is interfering with daily functioning, professional support is warranted. Stimulant-specific counseling, cognitive behavioral therapy, and peer support groups (such as SMART Recovery or Narcotics Anonymous) are applicable. There are no prolintane-specific withdrawal management protocols — treatment follows general stimulant use disorder guidelines.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Chest pain, rapid or irregular heartbeat
- Seizure or loss of consciousness
- Severe agitation, paranoia, or hallucinations that cannot be talked through
- Body temperature that feels dangerously hot to the touch
- Confusion or inability to follow simple instructions
Immediate steps:
- 1. Call emergency services immediately if any of the above are present.
- 2. Move the person to a cool, quiet environment.
- 3. Do not restrain unless there is immediate danger of self-harm.
- 4. If unconscious but breathing, place in the recovery position.
- 5. Do not induce vomiting.
- 6. Stay with the person until help arrives.
What to tell the dispatcher: Name the substance (prolintane, a stimulant), approximate amount and time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Prolintane occupies an unusual regulatory position: it is not specifically scheduled under controlled substances legislation in most major jurisdictions, yet it has been withdrawn from pharmaceutical markets and prohibited in athletic competition. Its legal status varies considerably by country and is shaped more by pharmaceutical regulation than by drug scheduling frameworks.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not scheduled under the Controlled Substances Act; not FDA-approved | No specific federal scheduling. Prohibited in athletic competition by WADA and NCAA.[11][3] The Federal Analogue Act may apply if sold for human consumption. |
| United Kingdom | Covered by Psychoactive Substances Act 2016 | Not specifically scheduled under the Misuse of Drugs Act 1971. The PSA makes production, supply, and importation of psychoactive substances illegal, effectively prohibiting commercial distribution.citation needed |
| Australia | Schedule 4 (Prescription Only) | Formerly prescribed for fatigue and ADHD. Currently classified as prescription-only under the Therapeutic Goods Act.citation needed |
| Germany | Prescription-only | Listed in Anlage 1 AMVV (Arzneimittelverschreibungsverordnung), restricting availability to prescription dispensing.citation needed |
| Spain | Withdrawn from market | Katovit withdrawn in 2001 due to safety and abuse concerns.[8][7] No longer commercially available. |
| Canada | Status not established | No data found regarding prolintane's status under the Controlled Drugs and Substances Act (CDSA) or provincial pharmacy regulations.citation needed |
| WADA | Prohibited in competition | Listed under S6 Stimulants category on the WADA Prohibited List.[3] |
Analog act considerations
In the United States, prolintane's structural similarity to scheduled stimulants (notably pyrovalerone, which is Schedule V under federal law) may bring it within the scope of the Federal Analogue Act (21 U.S.C. § 813). This law treats substances "substantially similar" to Schedule I or II controlled substances as Schedule I when intended for human consumption. Whether prolintane meets the structural and pharmacological similarity thresholds for analog prosecution has not been tested in court.citation needed
references
- [1] ^abcdefghijklKastner N, Islam MN, Dybek M, Roth E, Heisinger S, Holy M, Jäntsch K, Walther D, Stockner T, Baumann MH, Brandt SD, Wallach J, Sitte HH, Kudlacek O (2025) Prolintane analogs as hybrid monoamine transporter ligands: Structural determinants and species differences. — The Journal of Biological Chemistry doi:10.1016/j.jbc.2025.110903
- [2] ^abNapoletano F, Schifano F, Corkery JM, Guirguis A, Arillotta D, Zangani C, Vento A (2020) The Psychonauts' World of Cognitive Enhancers — Frontiers in Psychiatry doi:10.3389/fpsyt.2020.546796
- [3]
- [4]
- [5]
- [6]